drugset / Trial / NCT00888381

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

NCT00888381

Phase 4 Completed 120 enrolled Seqirus
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to assess the efficacy and safety of CSL's 2009/2010 formulation of the Enzira vaccine.

Timeline

Start
2009-05
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular

Indications